Hamann J, Hartmann E, van Lier RA (Feb 1996). "Structure of the human CD97 gene: exon shuffling has generated a new type of seven-span transmembrane molecule related to the secretin receptor superfamily". Genomics. 32 (1): 144–7. doi:10.1006/geno.1996.0092. PMID8786105.
Langenhan T, Aust G, Hamann J (May 2013). "Sticky signaling--adhesion class G protein-coupled receptors take the stage". Science Signaling. 6 (276): re3. doi:10.1126/scisignal.2003825. PMID23695165. S2CID6958640.
Aust G, Wandel E, Boltze C, Sittig D, Schütz A, Horn LC, et al. (Apr 2006). "Diversity of CD97 in smooth muscle cells". Cell and Tissue Research. 324 (1): 139–47. doi:10.1007/s00441-005-0103-2. PMID16408199. S2CID36161414.
Wobus M, Vogel B, Schmücking E, Hamann J, Aust G (Dec 2004). "N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding". International Journal of Cancer. 112 (5): 815–22. doi:10.1002/ijc.20483. PMID15386373. S2CID25515098.
Park SJ, Lee KP, Kang S, Chung HY, Bae YS, Okajima F, et al. (Nov 2013). "Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells". Cellular Signalling. 25 (11): 2147–54. doi:10.1016/j.cellsig.2013.07.001. PMID23838008.
Veninga H, de Groot DM, McCloskey N, Owens BM, Dessing MC, Verbeek JS, et al. (Mar 2011). "CD97 antibody depletes granulocytes in mice under conditions of acute inflammation via a Fc receptor-dependent mechanism". Journal of Leukocyte Biology. 89 (3): 413–21. doi:10.1189/jlb.0510280. PMID21169517. S2CID21436547.
Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC, Tak PP (Apr 1999). "Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue". Arthritis and Rheumatism. 42 (4): 650–8. doi:10.1002/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S. PMID10211878.
Hoek RM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, Reedquist KA, et al. (Apr 2010). "Deletion of either CD55 or CD97 ameliorates arthritis in mouse models". Arthritis and Rheumatism. 62 (4): 1036–42. doi:10.1002/art.27347. PMID20131275.
Wobus M, Huber O, Hamann J, Aust G (Nov 2006). "CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway". Molecular Carcinogenesis. 45 (11): 881–6. doi:10.1002/mc.20262. PMID16929497. S2CID24924901.
Takahashi-Yanaga F, Sasaguri T (Apr 2008). "GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy". Cellular Signalling. 20 (4): 581–9. doi:10.1016/j.cellsig.2007.10.018. PMID18023328.
Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, et al. (Mar 2005). "Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines". Thyroid. 15 (3): 222–31. doi:10.1089/thy.2005.15.222. PMID15785241.
Hamann J, Hartmann E, van Lier RA (Feb 1996). "Structure of the human CD97 gene: exon shuffling has generated a new type of seven-span transmembrane molecule related to the secretin receptor superfamily". Genomics. 32 (1): 144–7. doi:10.1006/geno.1996.0092. PMID8786105.
Langenhan T, Aust G, Hamann J (May 2013). "Sticky signaling--adhesion class G protein-coupled receptors take the stage". Science Signaling. 6 (276): re3. doi:10.1126/scisignal.2003825. PMID23695165. S2CID6958640.
Aust G, Wandel E, Boltze C, Sittig D, Schütz A, Horn LC, et al. (Apr 2006). "Diversity of CD97 in smooth muscle cells". Cell and Tissue Research. 324 (1): 139–47. doi:10.1007/s00441-005-0103-2. PMID16408199. S2CID36161414.
Wobus M, Vogel B, Schmücking E, Hamann J, Aust G (Dec 2004). "N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding". International Journal of Cancer. 112 (5): 815–22. doi:10.1002/ijc.20483. PMID15386373. S2CID25515098.
Park SJ, Lee KP, Kang S, Chung HY, Bae YS, Okajima F, et al. (Nov 2013). "Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells". Cellular Signalling. 25 (11): 2147–54. doi:10.1016/j.cellsig.2013.07.001. PMID23838008.
Veninga H, de Groot DM, McCloskey N, Owens BM, Dessing MC, Verbeek JS, et al. (Mar 2011). "CD97 antibody depletes granulocytes in mice under conditions of acute inflammation via a Fc receptor-dependent mechanism". Journal of Leukocyte Biology. 89 (3): 413–21. doi:10.1189/jlb.0510280. PMID21169517. S2CID21436547.
Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC, Tak PP (Apr 1999). "Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue". Arthritis and Rheumatism. 42 (4): 650–8. doi:10.1002/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S. PMID10211878.
Hoek RM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, Reedquist KA, et al. (Apr 2010). "Deletion of either CD55 or CD97 ameliorates arthritis in mouse models". Arthritis and Rheumatism. 62 (4): 1036–42. doi:10.1002/art.27347. PMID20131275.
Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O, et al. (May 1997). "CD97: a dedifferentiation marker in human thyroid carcinomas". Cancer Research. 57 (9): 1798–806. PMID9135025.
Wobus M, Huber O, Hamann J, Aust G (Nov 2006). "CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway". Molecular Carcinogenesis. 45 (11): 881–6. doi:10.1002/mc.20262. PMID16929497. S2CID24924901.
Takahashi-Yanaga F, Sasaguri T (Apr 2008). "GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy". Cellular Signalling. 20 (4): 581–9. doi:10.1016/j.cellsig.2007.10.018. PMID18023328.
Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, et al. (Mar 2005). "Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines". Thyroid. 15 (3): 222–31. doi:10.1089/thy.2005.15.222. PMID15785241.
ncbi.nlm.nih.gov
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Langenhan T, Aust G, Hamann J (May 2013). "Sticky signaling--adhesion class G protein-coupled receptors take the stage". Science Signaling. 6 (276): re3. doi:10.1126/scisignal.2003825. PMID23695165. S2CID6958640.
Aust G, Wandel E, Boltze C, Sittig D, Schütz A, Horn LC, et al. (Apr 2006). "Diversity of CD97 in smooth muscle cells". Cell and Tissue Research. 324 (1): 139–47. doi:10.1007/s00441-005-0103-2. PMID16408199. S2CID36161414.
Wobus M, Vogel B, Schmücking E, Hamann J, Aust G (Dec 2004). "N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding". International Journal of Cancer. 112 (5): 815–22. doi:10.1002/ijc.20483. PMID15386373. S2CID25515098.
Veninga H, de Groot DM, McCloskey N, Owens BM, Dessing MC, Verbeek JS, et al. (Mar 2011). "CD97 antibody depletes granulocytes in mice under conditions of acute inflammation via a Fc receptor-dependent mechanism". Journal of Leukocyte Biology. 89 (3): 413–21. doi:10.1189/jlb.0510280. PMID21169517. S2CID21436547.
Wobus M, Huber O, Hamann J, Aust G (Nov 2006). "CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway". Molecular Carcinogenesis. 45 (11): 881–6. doi:10.1002/mc.20262. PMID16929497. S2CID24924901.